PRPO - トランスジェノミック （Precipio Inc.） トランスジェノミックPRPOのチャート
PRPOの企業情報
| symbol | PRPO |
|---|---|
| 会社名 | Precipio Inc （トランスジェノミック） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Precipio Inc. formerly Transgenomic Inc. is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market enabling the use of blood and other bodily fluids for diagnosis monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms including Sanger Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted. トランスジェノミックは米国のバイオ企業。コネチカットとネブラスカ州の臨床検査室で心臓、神経、ミトコンドリア異常、がん疾患の遺伝子検査を行う。また、分子遺伝学研究と分子診断用の遺伝子解析システム「ウェ―ブ」を製造、販売するほか、他社の生体計測装置を販売。また、機器の据え付け、保守、技術サポ―トを提供。 Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. |
| 本社所在地 | 4 Science Park New Haven CT 06511 USA |
| 代表者氏名 | Samuel D. Riccitelli サミュエルD.リッチェッテリ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 203-787-7888 |
| 設立年月日 | 35490 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 33人 |
| url | www.precipiodx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/prpo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -7.68800 |
| 終値（lastsale） | 0.3775 |
| 時価総額（marketcap） | 8741341.68 |
| 時価総額 | 時価総額（百万ドル） 7.40988 |
| 売上高 | 売上高（百万ドル） 2.74400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 11.07688 |
| 当期純利益 | 当期純利益（百万ドル） -31.59900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Precipio Inc revenues increased from $508K to $1.5M. Net loss applicable to common stockholders decreased 6% to $9.1M. Revenues reflect Service revenue net increase from $619K to $1.7M. Lower net loss reflects Warrant revaluation increase from $3K (expense) to $584K (income) Interest expense net decrease of 85% to $56K (expense). |
PRPOのテクニカル分析
PRPOのニュース
Precipio, Inc. (PRPO) Q4 2022 Earnings Call Transcript 2023/04/03 23:10:04 Seeking Alpha
Precipio, Inc. (NASDAQ:NASDAQ:PRPO) Q4 2022 Earnings Conference Call April 3, 2023 5:00 PM ETCompany ParticipantsIlan Danieli - CEOConference Call ParticipantsOperatorWelcome to the…
Precipio Earnings Preview 2023/03/31 14:00:35 Benzinga
Precipio (NASDAQ: PRPO ) is set to give its latest quarterly earnings report on Monday, 2023-04-03. Here''s what investors need to know before the announcement. Analysts estimate that Precipio will report an earnings per share (EPS) of $-0.14. Precipio bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide … Full story available on Benzinga.com
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call 2023/03/28 21:00:00 Wallstreet:Online
Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM ET NEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday, April 3rd at 5:00 PM ET. The call will include updates on the Company’s current core businesses. The conference
Precipio Ships First IV-Cell Order to Major US Healthcare System 2023/03/21 14:30:00 Wallstreet:Online
Products Division revenues begin to diversify beyond HemeScreen NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell, the Company’s proprietary cytogenetics cell culturing media, to a major US healthcare system. The healthcare system (unnamed for competitive reasons) has successfully
Stocks Under Consideration: Seelos Therapeutics, Inc. (NASDAQ:SEEL 4.08%), Precipio, Inc. (NASDAQ:PRPO -1.52%) 2023/03/10 18:45:12 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Stocks Under Consideration: Seelos Therapeutics, Inc. (NASDAQ:SEEL 4.08%), Precipio, Inc. (NASDAQ:PRPO -1.52%) appeared first on Stocks Equity .
Precipio Signs Additional Major HemeScreen Customer 2022/12/06 15:00:00 Wallstreet:Online
Customer to begin gradually onboarding panels in Q1-2023, potential $1.2M revenue at full capacity NEW HAVEN, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced a 4-year agreement with a new customer to bring HemeScreen technology into their lab. Based on volume information provided by the customer, revenues in Q1-2023
Precipio, Inc. (PRPO) Q3 2022 Earnings Call Transcript 2022/11/14 23:37:05 Seeking Alpha
Precipio, Inc. (NASDAQ:NASDAQ:PRPO) Q3 2022 Earnings Conference Call November 14, 2022 05:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Conference Call Participants…
Precipio Presents Poster on HemeScreen Study at Association of Molecular Pathology (AMP) 2022 Annual Conference 2022/11/07 15:30:00 Wallstreet:Online
Poster presents findings of a study of ~1000 patient samples demonstrating superior accuracy for HemeScreen MPN Assay NEW HAVEN, Conn., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) presented at the annual 2022 AMP conference a poster presentation of the results of a groundbreaking study, conducted in collaboration with faculty
Precipio And 2 Other Penny Stocks Insiders Are Aggressively Buying 2022/10/07 13:44:13 Benzinga
US gold futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform.3 Clear Channel Outdoor The Trade: Clear Channel Outdoor Holdings, Inc. (NYSE: CCO ) 10% owner Ares Partners Holdco LLC bought a total of 400,000 shares at an average price of $1.59. To … Full story available on Benzinga.com
Thinking Of Buying Precipio Inc. (NASDAQ: PRPO) Stock? Here Is What You Should Know 2022/09/17 16:00:00 Stocks Register
Precipio Inc. (NASDAQ:PRPO) shares, rose in value on Friday, 09/16/22, with the stock price down by -9.08% to the previous day’s close as strong demand from buyers drove the stock to $0.95. Actively observing the price movement in the last trading, the stock closed the session at $1.04, falling within a range of $0.91 and … Thinking Of Buying Precipio Inc. (NASDAQ: PRPO) Stock? Here Is What You Should Know Read More »
Precipio And 2 Other Penny Stocks Insiders Are Aggressively Buying 2022/10/07 13:44:13 Benzinga
US gold futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform.3 Clear Channel Outdoor The Trade: Clear Channel Outdoor Holdings, Inc. (NYSE: CCO ) 10% owner Ares Partners Holdco LLC bought a total of 400,000 shares at an average price of $1.59. To … Full story available on Benzinga.com
Thinking Of Buying Precipio Inc. (NASDAQ: PRPO) Stock? Here Is What You Should Know 2022/09/17 16:00:00 Stocks Register
Precipio Inc. (NASDAQ:PRPO) shares, rose in value on Friday, 09/16/22, with the stock price down by -9.08% to the previous day’s close as strong demand from buyers drove the stock to $0.95. Actively observing the price movement in the last trading, the stock closed the session at $1.04, falling within a range of $0.91 and … Thinking Of Buying Precipio Inc. (NASDAQ: PRPO) Stock? Here Is What You Should Know Read More »
How Could You Make A Quick Recovery From Precipio Inc. (NASDAQ: PRPO) Given A -284.62% Drop From Highs? 2022/09/16 15:00:00 Marketing Sentinel
During the last session, Precipio Inc. (NASDAQ:PRPO)’s traded shares were 3.01 million, with the beta value of the company hitting 2.08. At the end of the trading day, the stock’s price was $1.04, reflecting an intraday gain of 8.33% or $0.08. The 52-week high for the PRPO share is $3.13, that puts it down -200.96 … How Could You Make A Quick Recovery From Precipio Inc. (NASDAQ: PRPO) Given A -284.62% Drop From Highs? Read More »
Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™ 2022/09/15 15:00:00 GlobeNewswire
Adding customer segment exceeding $100M in market potential Adding customer segment exceeding $100M in market potential
Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen 2022/09/15 15:00:00 Wallstreet:Online
Adding customer segment exceeding $100M in market potential NEW HAVEN, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a distribution agreement for HemeScreen with a major distribution partner (name withheld as per partner’s policy). Following an upcoming training program and onboarding of their national coverage,